AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 Showing Large and Consistent Improvements in Social Anxiety Disorder
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 in Social Anxiety Disorder
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
QIMC Partners with Lambton College to Develop Hydrogen-Powered Modular Energy Systems for AI Data Centers
Awalé Reports New Discovery on 100%-Owned Ground with Multiple Shallow Intercepts, Including 17 Metres at 1.9 g/t Gold
New Found Gold Continues to Confirm Continuity of The AFZ Core and Intersect New Mineralization at Depth at The Queensway Gold Project
